Results 21 to 30 of about 407,106 (256)
Journal of the Formosan Medical Association, 2013 The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its ...
Wan-Ling Ho +8 more
doaj +1 more source
Cost Effectiveness and Resource Allocation, 2020 Background Cost-effectiveness analysis provides a crucial means for evidence-informed decision-making on resource allocation. This study aims to elicit individuals' willingness to pay (WTP) for one additional quality-adjusted life-year (QALY) gained from
Najmeh Moradi +4 more
doaj +1 more source
THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES
Фармакоэкономика, 2017 This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia, a standardized methodology to calculate QALY is in use; such an approach makes it possible to apply this universal criterion of effectiveness to the ...
N. Z. Musina, V. K. Fedyaeva
doaj +1 more source
SAGE Open Medicine, 2023 Objectives: Many patients with hormone-receptor positive breast cancer undergo prolonged treatment. However, the long-term patient quality of life assessment has not been examined.
Takenori Ichimura +2 more
doaj +1 more source
Putting the quality into quality-adjusted life years [PDF]
Journal of Public Health, 2003 Over recent decades, a great deal of effort has been devoted towards developing instruments that can be used to elicit health state values. All of these instruments are conceptually very different from one another and all suffer from serious inherent biases.
openaire +2 more sources
Quality-Adjusted Life-Years without Constant Proportionality [PDF]
Value in Health, 2018 A quality-adjusted life-year is a common unit of measurement in health valuation. Under its constant proportionality assumption, the value of a quality-adjusted life span is defined as the product of preference weight and life span.To empirically identify an alternative functional relationship between life span and value by relaxing the constant ...
Craig, Benjamin M. +3 more
openaire +3 more sources
BMC Gastroenterology, 2020 Background Cabozantinib was approved by the European Medicines Agency and the Federal Drug Administration as an option for sorafenib-resistant advanced hepatocellular carcinoma, increasing overall survival and progression-free survival compared with ...
Maximilian Sieg +3 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Introduction Characterizing stressful events reported by childhood cancer survivors experienced throughout the lifespan may help improve trauma‐informed care relevant to the survivor experience. Methods Participants included 2552 survivors (54% female; 34 years of age) and 469 community controls (62% female; 33 years of age) from the St.
Megan E. Ware +13 more
wiley +1 more source
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
PLoS ONE, 2022 AimsA Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with ...
Carlos Escobar Cervantes +10 more
doaj +2 more sources
BMC Health Services Research, 2023 Background The incidence and mortality rates of patients with chronic lymphocytic leukemia (CLL) in China have recently increased. This study performed a long-term economic evaluation of the first-line treatment strategies ibrutinib (IB) or bendamustine (
Yuan Hong +9 more
doaj +1 more source